LIFECORE BIOMEDICAL, INC. Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax of $282.00 thousand for the 12-month period ending 2019-05-26, per its 10-K filed 2019-08-01.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax · last filed 2020-04-03
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2019-05-26 was $92.00K, a 78.55% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2019-02-24 was $215.00K.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2018-11-25 was -$23.00K, a 116.43% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2018-08-26 was $27.00K, a 52.63% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2019 was $282.00K.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2018 was -$123.00K.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2017 was -$254.00M.
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2016 was $0.00.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-05-26 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-01 | $307.00K derived: sum of 2 quarters · filed 2020-04-03 | $284.00K derived: sum of 3 quarters · filed 2020-04-03 | $282.00K 10-K · filed 2019-08-01 | ||||
| 2019-02-24 | $215.00K 10-Q · filed 2020-04-03 | $192.00K derived: sum of 2 quarters · filed 2020-04-03 | $190.00K 10-Q · filed 2020-04-03 | $648.00K derived: sum of 4 quarters · filed 2020-04-03 | ||||
| 2018-11-25 | -$23.00K 10-Q · filed 2020-01-02 | $53.00K 10-Q · filed 2019-01-07 | $4.00K 10-Q · filed 2020-01-02 | -$25.00K 10-Q · filed 2019-01-07 | $433.00K derived: sum of 3 quarters · filed 2020-01-02 | $223.00K derived: sum of 4 quarters · filed 2020-01-02 | ||
| 2018-08-26 | $27.00K 10-Q · filed 2019-10-03 | $456.00K derived: sum of 2 quarters · filed 2019-10-03 | $246.00K derived: sum of 3 quarters · filed 2019-10-03 | $386.00K derived: sum of 4 quarters · filed 2019-10-03 | ||||
| 2018-05-27 | $429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-01 | $219.00K derived: sum of 2 quarters · filed 2019-08-01 | $359.00K derived: sum of 3 quarters · filed 2019-08-01 | -$123.00K 10-K · filed 2019-08-01 | $123.00K 10-K · filed 2018-08-09 | |||
| 2018-02-25 | -$210.00K 10-Q · filed 2019-04-04 | $210.00K 10-Q · filed 2018-04-05 | -$70.00K derived: sum of 2 quarters · filed 2019-04-04 | -$552.00K 10-Q · filed 2019-04-04 | $552.00K 10-Q · filed 2018-04-05 | -$254.26M derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2017-11-26 | $140.00K 10-Q · filed 2019-01-07 | -$85.00K 10-Q · filed 2019-01-07 | $85.00K 10-Q · filed 2018-01-05 | -$254.05M derived: sum of 3 quarters · filed 2019-08-01 | -$254.00M derived: sum of 4 quarters · filed 2019-08-01 | |||
| 2017-08-27 | $57.00K 10-Q · filed 2018-10-05 | -$254.19M derived: sum of 2 quarters · filed 2019-08-01 | -$254.13M derived: sum of 3 quarters · filed 2019-08-01 | -$253.94M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2017-05-28 | -$254.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-01 | -$254.19M derived: sum of 2 quarters · filed 2019-08-01 | -$254.00M derived: sum of 3 quarters · filed 2019-08-01 | -$254.00M 10-K · filed 2019-08-01 | $254.00 10-K · filed 2017-08-11 | |||
| 2017-02-26 | $59.00K 10-Q · filed 2018-04-05 | $251.00K derived: sum of 2 quarters · filed 2018-04-05 | $251.00K 10-Q · filed 2018-04-05 | |||||
| 2016-11-27 | $192.00K 10-Q · filed 2018-01-05 | $192.00K 10-Q · filed 2018-01-05 | ||||||
| 2016-05-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-09 | $0.00 derived: sum of 2 quarters · filed 2018-08-09 | $0.00 derived: sum of 3 quarters · filed 2018-08-09 | $0.00 10-K · filed 2018-08-09 | ||||
| 2016-02-28 | $0.00 10-Q · filed 2017-04-07 | $0.00 derived: sum of 2 quarters · filed 2017-04-07 | $0.00 10-Q · filed 2017-04-07 | |||||
| 2015-11-29 | $0.00 10-Q · filed 2017-01-05 | $0.00 10-Q · filed 2017-01-05 | ||||||
| 2015-05-31 | $0.00 10-K/A · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |